2/11
06:41 pm
vnda
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]
2/11
06:28 pm
vnda
Vanda Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Vanda Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
2/11
04:16 pm
vnda
Vanda Pharmaceuticals GAAP EPS of -$2.39 misses by $1.07, revenue of $57.22M misses by $2.05M [Seeking Alpha]
Medium
Report
Vanda Pharmaceuticals GAAP EPS of -$2.39 misses by $1.07, revenue of $57.22M misses by $2.05M [Seeking Alpha]
2/11
04:01 pm
vnda
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
2/4
06:01 pm
vnda
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Medium
Report
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
2/3
01:40 pm
vnda
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
1/29
10:00 am
vnda
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
1/27
01:08 pm
vnda
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
1/22
10:00 am
vnda
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
1/20
01:11 pm
vnda
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
1/15
10:00 am
vnda
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
1/13
03:49 pm
vnda
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
1/8
09:06 am
vnda
Vanda Pharmaceuticals Says FDA Rejects Hetlioz as Jet Lag Treatment [Yahoo! Finance]
Low
Report
Vanda Pharmaceuticals Says FDA Rejects Hetlioz as Jet Lag Treatment [Yahoo! Finance]
1/8
07:00 am
vnda
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
Low
Report
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
1/6
08:27 am
vnda
Assessing Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of NEREUS For Motion Sickness [Yahoo! Finance]
Low
Report
Assessing Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of NEREUS For Motion Sickness [Yahoo! Finance]
1/5
07:17 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/5
07:17 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
1/3
01:08 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by analysts at
Wall Str
Medium
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by analysts at
Wall Str
1/2
01:29 pm
vnda
Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn't (Rating Downgrade) [Seeking Alpha]
Low
Report
Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn't (Rating Downgrade) [Seeking Alpha]
1/1
08:30 am
vnda
Vanda Pharmaceuticals price target raised to $14 from $11 at B. Riley [Yahoo! Finance]
Medium
Report
Vanda Pharmaceuticals price target raised to $14 from $11 at B. Riley [Yahoo! Finance]
1/1
07:41 am
vnda
Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus [Seeking Alpha]
Medium
Report
Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus [Seeking Alpha]
12/31
09:12 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at B. Riley.
Medium
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at B. Riley.
12/31
06:01 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "hold" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Medium
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "hold" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/31
05:16 am
vnda
Biggest stock movers Wednesday: Vanda Pharmaceuticals and Cybin [Seeking Alpha]
Medium
Report
Biggest stock movers Wednesday: Vanda Pharmaceuticals and Cybin [Seeking Alpha]
12/30
07:42 pm
vnda
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness [Yahoo! Finance]
Medium
Report
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness [Yahoo! Finance]